For: | Gordon M, Lakunina S, Sinopoulou V, Akobeng A. Minimum sample size estimates for trials in inflammatory bowel disease: A systematic review of a support resource. World J Gastroenterol 2021; 27(43): 7572-7581 [PMID: 34887650 DOI: 10.3748/wjg.v27.i43.7572] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v27/i43/7572.htm |
Number | Citing Articles |
1 |
Vassiliki Sinopoulou, Morris Gordon, Vicki Gregory, Anas Saadeh, Anthony K Akobeng. Prebiotics for induction and maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2024; 2024(3) doi: 10.1002/14651858.CD015084.pub2
|
2 |
Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Arni Sarian, Gordon William Moran. Infliximab for maintenance of medically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews 2024; 2024(2) doi: 10.1002/14651858.CD012609.pub2
|
3 |
Hongsheng Yang, Zhaopeng Huang, Miao Li, Haiyan Zhang, Lingyu Fu, Xiaoling Wang, Qiaoqiao Yang, Yun He, Wenhong Wu, Taofeng Jiang, Zhimei Sun, Tao Zhang, Dongping Lai, Xixin Wu, Lishuo Shi, Qin Guo, Yanhui Wu, Jian Tang, Kang Chao, Xiang Gao. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study. eClinicalMedicine 2023; 66: 102337 doi: 10.1016/j.eclinm.2023.102337
|
4 |
Samuel Hui, Vassiliki Sinopoulou, Morris Gordon, Ghazaleh Aali, Anuj Krishna, Nik Sheng Ding, Ray K Boyapati. Vedolizumab for induction and maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2023; 2023(7) doi: 10.1002/14651858.CD013611.pub2
|
5 |
Chris Wallace, Morris Gordon, Vassiliki Sinopoulou, Berkeley N Limketkai. Vitamin D for the treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews 2023; 2023(10) doi: 10.1002/14651858.CD011806.pub2
|
6 |
Antonio Facciorusso, Viktor Domislovic, Lorenzo Fuccio, Ivo Boskoski, Cristiano Spada, Gabriele Capurso, Marianna Arvanitakis, Marcello Maida. Principle of sample size calculation in gastroenterology research: a practical guide for clinicians. Expert Review of Gastroenterology & Hepatology 2024; 18(10): 561 doi: 10.1080/17474124.2024.2416239
|
7 |
James P Franciosi, Morris Gordon, Vassiliki Sinopoulou, Evan S Dellon, Sandeep K Gupta, Craig C Reed, Carolina Gutiérrez-Junquera, Rajitha D Venkatesh, Elizabeth A Erwin, Abdullah Egiz, Assem Elleithy, Edward B Mougey. Medical treatment of eosinophilic esophagitis. Cochrane Database of Systematic Reviews 2023; 2023(7) doi: 10.1002/14651858.CD004065.pub4
|
8 |
Sailish Honap, Vipul Jairath, Silvio Danese, Laurent Peyrin-Biroulet. Navigating the complexities of drug development for inflammatory bowel disease. Nature Reviews Drug Discovery 2024; 23(7): 546 doi: 10.1038/s41573-024-00953-0
|
9 |
Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Shellie J Radford, Mohsen Eldragini, Ana-Maria Darie, Gordon William Moran. Infliximab for medical induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2023; 2023(12) doi: 10.1002/14651858.CD012623.pub2
|
10 |
Aamer Imdad, Natasha G Pandit, Muizz Zaman, Nathan Zev Minkoff, Emily E Tanner-Smith, Oscar G Gomez-Duarte, Sari Acra, Maribeth R Nicholson. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews 2023; 2023(4) doi: 10.1002/14651858.CD012774.pub3
|
11 |
Vassiliki Sinopoulou, Morris Gordon, Gordon William Moran, Abdullah Mohammed Abousaleh ma Egiz, Sanjana Phlananthachai, Aditi Rane, Ahmed Hussein Ali Al-Tameemi. Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review. BMJ Open Gastroenterology 2024; 11(1): e001334 doi: 10.1136/bmjgast-2023-001334
|